Tevogen Bio Expanding Its Pipeline To Include Non-Oncology Products, An Approach Aimed At Maximizing ROI From Its ExacTcell Technology
Tevogen Bio Expanding Its Pipeline To Include Non-Oncology Products, An Approach Aimed At Maximizing ROI From Its ExacTcell Technology
- Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.
- Expanding its pipeline to include non-oncology products, an opportunistic approach aimed at maximizing ROI from its ExacTcell technology.
- 開發治療產品，不僅治療癌症，還可使腫瘤患者保持不間斷的治療。
- 擴大其產品線以包括非腫瘤產品，這是一種機會主義的方法，旨在最大化其ExacTcell技術的回報率。
WARREN, N.J., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces updates on its growing therapeutic pipeline, designed to meet the high unmet needs of cancer patients. The company is pursuing a prudent commercialization strategy with a focus on its ExacTcell technology platform, which leverages precision T cell therapies to address supportive care for cancer patients.
2024年10月11日，新澤西州禾倫（WARREN, N.J.）(環球新聞社)——Tevogen Bio（"Tevogen"或"Tevogen生物控股有限公司")（納斯達克:TVGN），一家臨床階段的專科免疫療法生物技術公司，正在開發成品、未經基因修改的t細胞治療產品，用於治療傳染病和癌症，宣佈對其不斷增長的治療產品線的更新，旨在滿足癌症患者的高度未滿足需求。該公司正在實施一項審慎的商業化策略，專注於其ExacTcell技術平台，利用精確的t細胞療法來解決癌症患者的支持性護理。
譯文內容由第三人軟體翻譯。
